SCHEMBL31078937

CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1CCCCCOCCOCCNC(=O)NCCCOCC(COCCCNC(=O)NCCOCCOCCCCC[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)(COCCCNC(=O)NCCOCCOCCCCC[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)NC(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 11)

	gene	UniProt	supporting neighbours	confidence
▸	HRAS	P01112	1/20	0.38

▸	LMNA	P02545	1/20	0.37

▸	SMN1; SMN2	Q16637	1/20	0.37

▸	HEXA	P06865	1/20	0.37

▸	MAPK1	P28482	1/20	0.35

▸	EPHX2	P34913	1/20	0.34

▸	ITGB3	P05106	1/20	0.34

▸	ITGA2B	P08514	1/20	0.34

▸	TACR1	P25103	1/20	0.34

▸	MDK	P21741	1/20	0.33

▸	OGA	O60502	1/20	0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30980620	0.91	HRAS (0.39)	HRASLMNASMN1; SMN2HEXAOGA
SCHEMBL30980607	0.89	MDK (0.40)	HRASLMNASMN1; SMN2HEXAMDK
SCHEMBL30980659	0.86	LMNA (0.41)	HRASLMNASMN1; SMN2HEXA
SCHEMBL30980664	0.85	LMNA (0.41)	HRASLMNASMN1; SMN2HEXA
SCHEMBL30980522	0.81	MAPK1 (0.43)	SMN1; SMN2MAPK1MDKOGA
SCHEMBL31078828	0.78	MDK (0.36)	MAPK1MDKOGA
SCHEMBL30634609	0.78	MAPK1 (0.46)	HRASMAPK1MDK
SCHEMBL30587044	0.78	MAPK1 (0.46)	HRASMAPK1MDK
SCHEMBL30980757	0.77	MAPK1 (0.46)	SMN1; SMN2MAPK1MDK
SCHEMBL30980606	0.76	MAPK1 (0.47)	SMN1; SMN2MAPK1MDKOGA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-4651904-A1	LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF AUTOANTIBODIES	Lycia Therapeutics, Inc. (US)	2025-11-26	—	—	EP	disclosed
WO-2024155750-A1	LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF AUTOANTIBODIES	LYCIA THERAPEUTICS, INC. (US)	2024-07-25	—	—	WO	disclosed